Maternal Fetal Alloimmune diseases of pregnancy

Johnson & Johnson aims to help address the unmet needs persisting for families impacted by alloimmune diseases of pregnancy, including Fetal and neonatal alloimmune thrombocytopenia (FNAIT) and Hemolytic disease of the fetus and newborn (HDFN), by pioneering an innovative approach that may change the course of treatment for these conditions in the future.